

Proteomics and bioinformatics and the future of personalized medicine

Editorial

MedCrave Online Journal for Proteomics and Bioinformatics (MOJPB) is a scientific journal that will gain increasing recognition in upcoming years. I am very happy to become a member of the team as an associate editor. I believe the visibility of the journal will be enhanced over the next five years, allowing the recruitment of innovative studies that will allow a steep rise in its impact factors.

A key objective of personalized medicine is to translate proteomics and bioinformatics information into clinical practice and health care delivery to patients. Thus, MOJPB journal has an ideal format to recruit ground-breaking articles that relate to translational medicine. Importantly, these types of manuscripts bring together teams of basic scientists and clinicians. MOJPB will contribute to integrate these important fields thus allowing better customized patient care. MOJPB is the perfect vessel to deliver such translational articles to the scientific community and I predict this will continue to contribute to its rapid growth within the next few years.

In summary, proteomics and bioinformatics are the future of personalized medicine. Having translational publications in MOJPB will contribute to the dissemination of new laboratory diagnostics leading to improved patient health. Very few currently available online journals have such a rare opportunity to contribute directly to

Volume 1 Issue 2 - 2014

Isabelle Mercier

Department of Pharmaceutical Sciences, University of the Sciences, USA

Correspondence: Isabelle Mercier, Department of Pharmaceutical Sciences, Philadelphia College of Pharmacy (PCP), University of the Sciences, 600 S. 43rd St. PTC Building room # 238, Philadelphia, PA 19104, USA, Email isa.mercier1@gmail.com

Received: June 17, 2014 | **Published:** June 18, 2014

patients care through the publications of clinically relevant studies that have translational value. It is thus my pleasure to be part of the journal to continue its journey to deliver personalized medicine care to patients and to guide them towards informed treatment decisions.

Acknowledgements

None.

Conflict of interest

The author declares no conflict of interest.